Abbott acquired exclusive rights for FGFR3 gene mutations for use in bladder cancer from Institut Curie. The FGFR3 biomarker has been shown to provide early detection of early-stage bladder cancer and predicting patient recurrences. This license allows Abbott to expand its scientific commitment in molecular diagnostics and bladder cancer.
“We are pleased to partner with Abbott given their deep expertise in molecular and companion diagnostics. Our agreement helps Institut Curie optimize the clinical utility of FGFR3, and we are looking forward to combining our strengths with Abbott to create a diagnostic to help improve care for bladder cancer patients,” says Damien Salauze, Vice President, business development and licensing, Institut Curie.
Activating FGFR3 gene mutations are seen in about 70 percent of low-grade and 15 to 20 percent of high-grade bladder cancer cases. Nearly 75,000 new cases of bladder cancer are diagnosed in the U.S. every year, according to the National Cancer Institute. According to Monica Smith, executive director at the Bladder Cancer Advocacy Network, the FGFR mutation discovery is just one example of promising research to better understand bladder cancer and improve patient outcomes.
Learn more on the Abbott website
